ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

New AIDs System For Classification Increase By 1% Cases Reported

August 1, 1986

Cooperative Groups Start To Deploy Medidata Rave, Despite Contract Dispute

April 22, 2011

Vanderbilt, Jonsson Centers Win NCI SPORE Grants.

May 18, 2001

Aging Institute Encourages Cancer Investigators To Include Elderly

January 8, 1982

On Biomedical Malthusianism; Varmus, et al. Propose a Strategy For Saving Biomedical Research

May 2, 2014

Boyd Steps Down As DTP Director, Returns to Research

February 16, 1990